Loading
A phase 3 trial testing AZD5335 in ovarian cancer, now recruiting.
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer is a phase 3 interventional study registered as NCT07218809, led by AstraZeneca with European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation and Ventana Medical Systems, and recruiting on the registry. Official title: A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01). Planned enrolment is 1100 participants (estimated). The study started in 2025-12-29 and primary completion is expected in 2028-11-17. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AZD5335, AstraZeneca, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/